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replacement (TAVR) approach in patients not eligible for transfemoral (TF) access by using a device commercially
available in the United States.Background A large proportion of candidates for TAVR have inadequate iliofemoral vessels for TF access. The transapical
route (TAP) is the current alternative but is associated with less favorable outcomes. Other access options need
to be explored.Methods Forty-four consecutive patients with inoperable, severe aortic stenosis underwent TAO TAVR in our institution.
Procedural and 30-day clinical outcomes data were compared with data from 76 consecutive patients who
underwent TAP TAVR at our site. Technical learning curves were assessed by comparing outcomes of the ﬁrst
20 cases with the subsequent patients who underwent each procedure.Results The TAO and TAP TAVR groups were similar in terms of device success according to Valve Academic Research
Consortium criteria (89% vs. 84%; p ¼ 0.59) and rates of the 30-day combined safety endpoint of all-cause
mortality, myocardial infarction, major stroke, disabling bleeding, severe acute kidney injury, and valve
reintervention (20% vs. 33%; p ¼ 0.21). The TAO approach, compared with TAP TAVR, was associated with lower
combined bleeding and vascular event rate (27% vs. 46%; p ¼ 0.05), shorter median intensive care unit length of
stay (3 vs. 6 days; p ¼ 0.01), and a favorable learning curve.Conclusions TAVR via the TAO approach is technically feasible, seems to be associated with favorable outcomes, and expands
the current alternative options for access sites in patients with inoperable aortic stenosis who are ineligible for TF
TAVR. (J Am Coll Cardiol 2013;61:2341–5) ª 2013 by the American College of Cardiology FoundationTranscatheter aortic valve replacement (TAVR) has revolu-
tionized the management of severe aortic stenosis (AS) in
patients who are at high risk or ineligible for surgical
aortic valve replacement (SAVR). The Edwards SAPIEN
(Edwards Lifesciences, Irvine, California) transcatheter
heart valve (THV) with its RetroFlex 3 delivery system, the
ﬁrst clinically available TAVR device in the United States,
was approved by the US Food and Drug Administration foral Heart Disease Program at the University
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2012; revised manuscript received February 26,transfemoral (TF) TAVR in patients with inoperable, severe
AS. However, a signiﬁcant proportion of patients who
would otherwise qualify for TAVR (up to 30% in the
PARTNER [Placement of Aortic Transcatheter Valves]
trial [1]) are excluded because of inadequate iliofemoral
vascular access. In these patients, the transapical (TAP) route
was the alternative method of device delivery. Unfortunately,
early experience with TAP TAVR suggests a trend toward less
favorable periprocedural outcomes (2) and a steep learning
curve (3). Thus, other access strategies need to be explored. We
describe our initial experience with the transaortic (TAO)
TAVR approach for the treatment of these patients.Methods
Forty-four consecutive patients underwent TAO TAVR
between January 2012 and June 2012 at our site and
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2342were enrolled in a prospective
database. All patients had symp-
tomatic (New York Heart Asso-
ciation class II to IV), inoperable,
severe AS and inadequate TF
vascular access. Severe AS was
deﬁned according to PARTNER
trial criteria (4), as was inoper-
ability that was formally deter-
mined by at least 2 cardiothoracic
surgeons. Iliofemoral access was
deemed inadequate if the mini-
mum vessel diameter was <7 mm
for a 23-mm valve (<8 mm for
a 26-mm valve) or if there were
vascular anatomic abnormalities
that precluded TF device delivery.The TAO TAVR procedure was performed in a hybrid
cardiac catheterization laboratory under general anesthesia
(Fig. 1). The operative steps are listed in Table 1.
Study outcomes. The main study outcomes were Valve
Academic Research Consortium–deﬁned acute technical
device success and 30-day combined safety endpoint. Acute
technical device success was deﬁned as successful vascular
access, successful delivery and deployment of a single valve
at the correct anatomic position, and appropriate prosthetic
valve function without signiﬁcant (moderate or severe)ranscatheter Aortic Valve Replacement P
eterization laboratory and the position of the operator
eter, and (3) a second interventional cardiologist deperivalvular regurgitation or stenosis; these assessments were
made by using echocardiography immediately after valve
deployment and before hospital discharge. The combined
safety outcome is a hierarchical composite of all-cause
mortality, major stroke, disabling bleeding, severe (stage 3)
acute kidney injury, postprocedure myocardial infarction,
major vascular complication, and repeat procedure for valve-
related dysfunction.
To evaluate the technical learning curve, the hierarchical
composite of intraprocedural adverse events (procedural
death, rescue cardiac surgery, valve reintervention, life-
threatening hemorrhage, major vascular complications,
myocardial infarction, and major stroke) was used to compare
the ﬁrst 20 cases with the subsequent patients who under-
went the operation. Length of stay (LOS) at the intensive
care unit (ICU) and total hospital LOS were also recorded.
All events were adjudicated by using the Valve Academic
Research Consortium criteria (5).
Comparator cohort. To evaluate the effect of the technical
learning curve and clinical safety of the TAO TAVR
approach, outcomes data were compared with data from
76 consecutive patients who underwent TAP TAVR at our
site from May 2009 to June 2012. TAP TAVR was per-
formed by using the SAPIEN THV and its dedicated
Ascendra delivery system, as described elsewhere (1).
Statistical analysis. Absolute numbers, percentages, and
medians were calculated to describe the population. Forrocedure
s are shown. (1) A cardiac surgeon secures the delivery sheath, (2) an interventional
ploys the valve.
Table 1 Step-by-Step Description of the TAO TAVR Procedure
A 2-inch midline skin incision was made on the chest just below the sternal notch.
A limited, upper “mini-J” sternotomy was performed at the second intercostal
space.
The innominate vein was identiﬁed and mobilized to expose the ascending aorta
below.
A suitable, noncalciﬁed area for aortotomy was identiﬁed.
A double purse-string suture of 4-0 Prolene was placed over the aortotomy site.
Intravenous heparin was administered for anticoagulation.
An 18-gauge needle was used to puncture the ascending aorta at the aortotomy
site.
A short 7-F sheath was inserted through the aortotomy over a guidewire.
The aortic valve was crossed with a 6-F pigtail catheter.
The catheter was exchanged with a 0.035-inch Amplatz Extra-Stiff guidewire*.
The 7-F sheath was exchanged with the RetroFlex 3 introducer sheath.
The introducer tip was advanced about 1 cm into the ascending aorta.
Balloon aortic valvuloplasty was performed by using an Edwards 23  30 mm
balloon catheter.
The transcatheter aortic valve prosthesis was deployed by using the RetroFlex 3
delivery catheter.
The introducer sheath was removed, and the purse-string sutures were tied to seal
the aortotomy.
A chest tube was inserted in the pericardium left of the aorta, exiting through the
right chest.
*Before insertion, the distal end of the stiff guidewire was bent into a large semicircular shape to
reduce risk of ventricle perforation.
TAO ¼ transaortic; TAVR ¼ transcatheter aortic valve replacement.
Table 2 Baseline Characteristics of Patients
Characteristic TAO (n ¼ 44) TAP (n ¼ 76) p Value
Median age (yrs) 85  5.6 87  5.8 0.18
Male 19 (43) 40 (53) 0.34
Median STS score 8.0  3.8 10.8  3.7 0.01
Inoperable for surgical AVR 44 (100) 10 (13) 0.01
NYHA class III or IV 39 (89) 64 (84) 0.59
Diabetes mellitus 10 (23) 19 (25) 0.83
Previous myocardial infarction 8 (18) 18 (24) 0.50
Previous coronary artery bypass
graft
9 (20) 38 (50) 0.01
Cerebrovascular disease 13 (30) 53 (70) 0.01
Peripheral vascular disease 32 (73) 57 (75) 0.83
Chronic obstructive pulmonary
disease
22 (50) 31 (41) 0.35
Baseline creatinine 2.0 mg/dl 3 (7) 14 (18) 0.10
Atrial ﬁbrillation 11 (25) 28 (37) 0.23
Pulmonary hypertension 9 (20) 10 (13) 0.31
Median aortic valve area (cm2) 0.65  0.15 0.61  0.44 0.42
Median LV ejection fraction (%) 60  14 58  14 0.45
Values are mean  SD or n (%).
AVR ¼ aortic valve replacement; LV ¼ left ventricular; NYHA ¼ New York Heart Association;
STS ¼ Society of Thoracic Surgeons; TAP ¼ transapical route; other abbreviation as in Table 1.
Table 3 Procedural and Clinical Outcomes by TAVR Approach
Outcome TAO (n ¼ 44) TAP (n ¼ 76) p Value
Device-related event
Acute technical device success 39 (89) 65 (86) 0.78
Implantation success 44 (100) 76 (100) 0.99
Moderate or severe ﬁnal residual
periprosthetic regurgitation
5 (11) 9 (12) 0.99
Leaﬂet entrapment/malcoaptation 0 (0) 2 (3) 0.53
Malposition/embolization 0 (0) 3 (4) 0.29
Implantation of 2 valves 0 (0) 5 (7) 0.16
Rescue surgical AVR 0 (0) 0 (0) 0.99
Procedural death 1 (2) 2 (3) 0.99
30-day clinical events
Combined clinical safety endpoint 9 (20) 22 (29) 0.50
All-cause death 6 (14) 11 (14) 0.99
CV mortality 1 (2) 9 (12) 0.09
Myocardial infarction 0 (0) 2 (2) 0.53
Major stroke 0 (0) 1 (1) 0.99
Minor stroke 1 (2) 0 (0) 0.37
Severe AKI (stage 3) 1 (2) 1 (1) 0.99
New atrial ﬁbrillation 6 (14) 15 (20) 0.32
New permanent pacemaker 1 (2) 5 (7) 0.41
Rescue cardiac surgery 3 (7) 1 (1) 0.14
Life-threatening bleeding 6 (14) 10 (13) 0.99
Major bleeding 5 (11) 21 (28) 0.04
Major vascular complications 1 (2) 4 (5) 0.65
Total bleeding and vascular events 12 (27) 35 (46) 0.05
Values are n (%).
AKI ¼ acute kidney injury; AVR ¼ aortic valve replacement; CV ¼ cardiovascular; other abbre-
viations as in Table 2.
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for continuous variables and the chi-square test or Fisher exact
test for categorical variables were used. A 2-tailed p value
of 0.05 was considered to indicate statistical signiﬁcance.
Results
The baseline demographic and clinical proﬁles of patients in
both groups were generally similar (Table 2). The TAP
group had a higher median Society of Thoracic Surgeons
(STS) score, driven by a higher proportion of patients who
had previous coronary artery bypass graft and stroke. All
patients in the TAO group were deemed inoperable,
whereas most patients in the TAP group were eligible for
SAVR.
THV implantation was successful in all patients in the
TAO and TAP groups. Thirty-nine patients (89%) in the
TAO group met the Valve Academic Research Consortium–
deﬁned criteria for acute technical device success, compared
with 64 (84%) in the TAP group (p ¼ 0.59). The proportion
of patients with signiﬁcant residual perivalvular regurgita-
tion was also similar between groups (Table 3). In the
TAP group, 3 cases (4%) of valve malposition/embolization
occurred, and 5 patients (7%) required rescue valve-in-valve
TAVR. No such device-related complications were re-
ported in the TAO group.
One patient in the TAO group and 2 patients in the TAP
group died during the procedure. Two of these deaths (1 in
each group) resulted from aortic root perforation during
valve deployment. The other intraoperative mortality in the
TAP group was due to myocardial infarction resulting fromobstruction of the left coronary ostium by the implanted
prosthesis.
At 30 days, the combined safety endpoint was similar
between the TAO and TAP groups (20% vs. 33%, respectively;
p ¼ 0.21). Rates of all-cause death were identical between
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was cardiovascular (CV)-related (intraprocedural mortality),
whereas 9 (82%) of the 11 deaths in the TAP group were
adjudicated as CV mortality (p ¼ 0.02). Causes of non-CV
deaths in the TAO group were pneumonia-related respira-
tory failure (4 cases) and Clostridium difﬁcile sepsis (1 case).
The incidence of life-threatening/disabling bleeding did
not differ between groups. However, the rate of major
bleeding was higher in the TAP group compared with the
TAO group (28% vs. 11%, respectively; p ¼ 0.04), as was
the incidence of total bleeding and vascular complications
(46% vs. 27%, respectively; p ¼ 0.05). On average, patients
in the TAP group stayed twice as long in the ICU as the
TAO group (6 vs. 3 days; p ¼ 0.01). Median hospital LOS
was also lower in the TAO group, but this ﬁnding was not
statistically signiﬁcant (Fig. 2).
The rates of composite intraprocedural adverse events
did not differ between the ﬁrst 20 cases and the subsequent
56 patients who underwent TAP TAVR (15% vs. 14%,
respectively; p ¼ 0.99). However, procedural adverse events
occurred exclusively in the ﬁrst 20 patients who underwent
TAO TAVR (20% vs. 0%; p ¼ 0.04), suggesting a more
favorable technical learning curve (Fig. 3).Figure 3 Learning Curve
The procedural learning curve outcomes according to the TAVR approach are
presented. In the TAO group (top), procedural adverse events were signiﬁcantly
reduced after the ﬁrst 20 cases. This observation was not seen in the TAP group
(bottom). Abbreviations as in Figures 1 and 2.Discussion
Although the TAP approach is an effective option for
TAVR (6), the need for alternative access strategies remains.
In the FRANCE 2 (French Aortic National CoreValve and
Edwards) Registry (7) of nearly 3,200 TAVR patients, TAP
access was an independent predictor of decreased survival.
Also, a trial that sought to compare TAP TAVR with
conventional SAVR was prematurely terminated due to
excess adverse events with the TAP approach (2).Figure 2 Length of Stay
The intensive care unit (ICU) and hospital lengths of stay (LOS) using the trans-
catheter aortic valve replacement (TAVR) approach are displayed. ICU LOS was
signiﬁcantly lower in the transaortic (TAO) group than in the transapical route (TAP)
group. There was also a nonsigniﬁcant trend toward lower total hospital LOS with
TAO TAVR.Our ﬁndings demonstrate that the TAO approach is
technically feasible in patients with inoperable, severe AS
who are ineligible for TF TAVR. In our cohort, TAO
TAVR was associated with lower bleeding rates, shorter
ICU stay, and more favorable learning curve compared with
the TAP approach.
Multiple transfusions during cardiac surgery are associated
with increased mortality and morbidity (8). Efforts to reduce
operative blood loss are likely as important in TAVR. In
28% of TAP patients in our series, signiﬁcant blood loss
occurred during access site closure. In the TAP approach,
hemostasis at the left ventricular apex was sometimes difﬁ-
cult to attain by using purse-string sutures. This does not
seem to be an issue with the TAO approach, as the double
purse-string sutures provided excellent seal of the aortotomy
(a routine maneuver for cardiothoracic surgeons who are
experienced with cannulating the aorta). This success
contributed to a signiﬁcant 61% relative reduction in peri-
operative blood transfusions in TAO TAVR compared with
TAP TAVR.
A cost-effectiveness analysis of the PARTNER trial
found that TAP TAVR was associated with substantially
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minimal reduction in ICU and hospital LOS (9). This
information is vital for any institution starting a TAVR
program. In our series, ICU LOS was signiﬁcantly longer in
TAP TAVR patients, owing to a longer duration of severe
surgical site pain and higher incidence of signiﬁcant post-
thoracotomy pleural effusion that complicated postoperative
pulmonary function.
As with other new devices and modalities, TAVR requires
a certain period for operator training and familiarization. In
our study, the technical learning curve for TAO TAVR
seemed favorable, as major intraprocedural adverse events
were effectively averted after the ﬁrst 20 cases. There was also
a trend toward a reduction in clinical events and mortality in
the TAO group with increasing operator experience. This
pattern was not observed with TAP TAVR, implying
a steeper learning curve and a larger number of procedures
required for proﬁciency. A signiﬁcant learning effect was
previously demonstrated in a cohort of approximately 300
TAP TAVR patients, in whom a sharp decline in morbidity
and mortality was noted after the ﬁrst 150 cases (3).
Device malposition was reported in 3 patients and need
for second THV implantation was required in 5 patients, all
in the TAP group. Left ventricular contractions induced
signiﬁcant movement of the introducer sheath in the TAP
route, which made manipulation and positioning of the
THV across the native valve difﬁcult. Conversely, we
observed very little movement of the introducer sheath with
TAO access, resulting in more stable and controlled posi-
tioning and deployment of the THV.
To the best of our knowledge, our series is the largest
cohort of patients who underwent TAO TAVR in the
United States to date. A similar preliminary experience was
reported in Europe with comparable clinical outcomes (10).
However, the European study used a newer-generation
THV (SAPIEN XT) and delivery system (Ascendra2),
which were not available in the United States at the time of
the study. Our TAO TAVR program was discontinued with
implementation of the 2012 Medicare national coverage
determinations for TAVR (11). Our study was completed
before the Ascendra delivery system (the original TAP
platform) was approved by the U.S. Food and Drug
Administration for clinical use in the United States, and
therefore comparative data between the use of TF and TAP
delivery devices in TAO TAVR are lacking. Finally, the use
of delivery systems not speciﬁcally designed for TAO
TAVR can lead to technical issues during device delivery
(12). Therefore, development of a dedicated delivery system
for TAO TAVR is recommended to improve the safety and
efﬁcacy of this procedure.
Study limitations. This was a nonrandomized, single-center
registry study that is subject to unmeasurable confounders.
The comparison of patients was taken from 2 different time
periods, which may have inﬂuenced the learning curve for
the TAO procedure. The TAP group also had a higher
median STS score compared with the TAO group, and thisﬁnding could also have potentially inﬂuenced the outcomes.
Larger randomized clinical trials are necessary to conﬁrm
our results.
Conclusions
TAVR via the TAO approach, using the device commer-
cially available in the United States, is technically feasible
and seems to be associated with favorable outcomes in
patients with inoperable, severe AS who are not candidates
for TF access. The TAO approach expands the current
alternative options for TAVR access sites, and development
of a dedicated delivery platform is recommended to further
improve its efﬁcacy and safety.
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